Table 2.

Univariate analysis for factors associated with risk of R/R disease after CD19 CAR T-cell therapy

	Univariate analysis
Parameter	HR (95% CI)	P
Age (>40 y vs ≤40 y)	1.11 (0.58-2.10)	.8
Sex (male vs female)	0.75 (0.37-1.55)	.5
Prior lines of treatment before CAR T cells (>3 vs ≤3)	1.55 (0.81-2.95)	.2
Philadelphia chromosome–positive ALL (yes vs no)	1.06 (0.54-2.07)	.9
Prior HSCT before CAR T cells (yes vs no)	1.43 (0.75-2.71)	.3
Prior blinatumomab before CAR T cells (yes vs no)	1.09 (0.53-2.25)	.8
Prior inotuzumab ozogamicin before CAR T cells (yes vs no)	0.93 (0.28-3.05)	.9
Bridging therapy before CAR T cells (no or nonintensive vs intensive therapy)	1.32 (0.64-2.71)	.4
Baseline LDH before lymphodepletion (normal vs high)	0.93 (0.48-1.83)	.8
Baseline platelet count before lymphodepletion (normal vs low)	0.73 (0.37-1.43)	.4
Disease status before lymphodepletion (morphologic vs MRD)	2.20 (1.09-4.41)	.02
Lymphodepletion chemotherapy (fludarabine-containing regimen vs cyclophosphamide)	1.05 (0.67-1.65)	.8
CRS (yes vs no)	0.73 (0.30-1.75)	.5
ICANS (yes vs no)	0.63 (0.33-1.20)	.2
Steroid exposure during CAR T-cell therapy (yes vs no)	0.98 (0.49-1.95)	.9
Tocilizumab exposure during CAR T-cell therapy (yes vs no)	1.35 (0.70-2.60)	.4
Duration of steroid exposure (d)	0.95 (0.83-1.08)	.4
Steroid dose intensity during CAR T-cell therapy (mg/kg/d)	0.77 (0.20-3.03)	.7
HSCT consolidation after CAR T-cell therapy	0.55 (0.23-1.32)	.2

LDH, lactate dehydrogenase.